Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors
Authors:
Top Cited Papers
Open Access
- 5 July 2024
- Vol. 187 (18) , 4905-4925.e24
Abstract
No abstract availableKeywords
This publication has 125 references indexed in Scilit:
- Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapyCancer Cell, 2023
- Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockadeCancer Cell, 2023
- Tumor-infiltrating regulatory T cells as targets of cancer immunotherapyCancer Cell, 2023
- The evolving tumor microenvironment: From cancer initiation to metastatic outgrowthCancer Cell, 2023
- Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapyCancer Cell, 2023
- Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancerCancer Cell, 2022
- Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer typesThe Journal of Pathology: Clinical Research, 2022
- Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancerCancer Cell, 2021
- Intratumor Heterogeneity: The Rosetta Stone of Therapy ResistanceCancer Cell, 2020
- Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in HumansCell, 2016